Biotinylated Human Fc gamma RIIIB / CD16b (NA1) Protein, His,Avitag™ (SPR & BLI verified)

Source : 

Biotinylated Human CD16b (NA1), His,Avitag (SPR & BLI verified) (CDB-H82E4) is expressed from human HEK293 cells. It contains AA Gly 17 - Ser 200 (Accession # AAA35881.1).
The NA1 form of the CD16b differ with the NA2 form of CD16b in AA36, 65, 82, and 106. The NA1 form carries R36, N65, D82, and V106, while the NA2 form carries S36, S65, N82, and I106.

 

Molecule : Fc gamma RIIIB / CD16b (NA1)

 

Synonyms : Fc gamma RIIIB / CD16b (NA1),FCGR3B,CD16B,FCG3B,FCGR3,FCG3,IGFR3

 

Format : Powder

 

Category : MABSol® Biotin Labeled Proteins

 

Accession : AAA35881.1

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 24.6 kDa

 

Characteristics :

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag. The protein has a calculated MW of 24.6 kDa. The protein migrates as 38-48 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : PBS, pH7.4

 

Description :

CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.
CD16B is also kown as FCGR3B and FCG3B, is expressed specifically by polymorphonuclear leukocytes (neutrophils) and stimulated eosinophils. CD16B is the low affinity receptor for the Fc region of immunoglobulins gamma. FCGR3B binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, FCG3B is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. CD16B may serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.

 

References :

(1) Ravetch J.V., et al., 1989, J. Exp. Med. 170:481-497.
(2) Gessner J.E., et al., 1995, J. Biol. Chem. 270:1350-1361.
(3) Bux J., et al., 1997, Blood 89:1027-1034.